Rapafusyn Pharmaceuticals

About Rapafusyn Pharmaceuticals

Rapafusyn is a biotechnology company pioneering RapaGlues™, a unique modality of non-degrading molecular glues designed to target previously intractable proteins. Their mission is to reshape medicine by bringing proteins together, creating novel therapies for underserved patients through innovative drug discovery.

Products & Services

RapaGlues™ Platform:A platform of non-degrading molecular glues that bring the intracellular chaperone protein FKBP12 in proximity with target proteins to block their native function. Benefits include permeability, selectivity, high tunability, and potential for oral delivery, targeting intracellular proteins like protein-protein interactions, transcription factors, and enzymes.

ENT1 Inhibitor (RAP-0001):A first-in-class clinical candidate targeting Equilibrative Nucleoside Transporter 1 (ENT1) to prevent acute kidney injury (AKI) in cardiac surgery patients by mitigating ischemia/reperfusion injury. It shows potential for broader applications in other ischemic conditions.

Pipeline Programs:Includes multiple programs in various stages (Hit Identification to DC to IND) such as ONC-001, ONC-005, ONC-006 (Oncology), IMM-001, IMM-002, IMM-003 (Immunology/Inflammation), and Discovery Programs targeting a range of intracellular and transmembrane proteins.

Specialties

Non-degrading Molecular Glues Drug Discovery for Intractable Targets Protein-Protein Interactions Intracellular and Transmembrane Protein Targeting Acute Kidney Injury Treatment Oncology Immunology/Inflammation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 44000000 MR: - FA: $44 million FAN: 44000000	D: 2025-09-04 FD: 2025-09-04	5 investors
2	RT: Series A T: - FT: Series A	A: 28000000 MR: - FA: 28 Million FAN: 28000000	D: 2024-06-20 FD: 2024-06-20	3 investors

Series A Latest

2025-09-04

$44.0M

5 investors (Pro only)

Series A 2024-06-20

$28.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sean X. Hu

CEO

R

Rick Ewing

Head of Medicinal Chemistry

S

Sam Hong

Head of Platform

M

Matthew Olson

Vice President of Biological Sciences

A

Alex Rabby

SVP Business Development

S

Shenjun Yan

Chairman of China Tianying Group and Adjunct Professor at Nanjing University

View 22 more team members with Pro

Unlock Full Team Directory

Recent News